Investor Relations Growth and Delivery

Filter by Year

2014 | 2013 | 2012

Keyword Search
 

2014 News Releases

 Previous | Next
April 24, 2014
Pride-HD Study Enrolling Patients Globally to Further Evaluate Pridopidine for the Symptomatic Treatment of Huntington’s Disease
– Study initiation represents significant milestone for patients with a disease with limited effective treatment options – JERUSALEM--(BUSINESS WIRE)--Apr. 24, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today enrollment of the first patient in The Pride-HD study, a phase II, randomized, double-blind, placebo-controlled global study designed to evaluate the impact of pridopidine, an investigational medication, on motor im  Read More »
April 19, 2014
Teva Announces Supreme Court Denial of Request for Interim Relief to Stay Court of Appeals Ruling for COPAXONE® Patent Due to the Potential for the Company to Recover Patent Infringement Damages
The Chief Justice Found That Teva Had Demonstrated “a Fair Prospect of Success on the Merits” JERUSALEM--(BUSINESS WIRE)--Apr. 19, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that while the Chief Justice of the United States found that Teva had demonstrated “a fair prospect of success on the merits” in its appeal of a decision from the United States Court of Appeals for the Federal Circuit that invalidated the claim of U.S  Read More »
April 17, 2014
Teva Settles Patent Litigation with Pfizer on Celebrex®
JERUSALEM--(BUSINESS WIRE)--Apr. 17, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today that its subsidiary Teva Pharmaceuticals USA, Inc. has entered into a settlement with Pfizer related to Teva’s generic version of Celebrex® (celecoxib) 50, 100, 200 and 400 mg capsules in the United States. Under the terms of the settlement, Teva may launch its generic versions in December, 2014, or earlier under certain circumstances. Teva has rec  Read More »
April 15, 2014
Teva Announces Launch of Generic Lunesta® Tablets in the United States
JERUSALEM--(BUSINESS WIRE)--Apr. 15, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announces the launch of the generic equivalent to Lunesta® (Eszopiclone Tablets, CIV), 1, 2 and 3 mg, in the United States. Lunesta® Tablets, marketed by Sunovion Pharmaceuticals, had annual sales of approximately $852 million in the United States, according to IMS data as of December 2013. About Teva Teva Pharmaceutical Indus  Read More »
April 08, 2014
Teva Announces First Approval and Launch of Generic Lovaza® Capsules in the United States
JERUSALEM--(BUSINESS WIRE)--Apr. 8, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announces the approval of the generic equivalent to Lovaza® (Omega-3-Acid Ethyl Esters Capsules, USP), in the United States. Teva believes it is first-to-file and thus far is the only Company to receive an approval from FDA. Teva plans to commence shipping immediately. Lovaza® Capsules, marketed by GlaxoSmithKline, had annual sales of approximately $  Read More »
March 31, 2014
Teva Announces U.S. Supreme Court Will Hear Its Appeal on COPAXONE® Patent
JERUSALEM--(BUSINESS WIRE)--Mar. 31, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that the U.S. Supreme Court has granted the Company’s COPAXONE® certiorari petition and will hear its appeal of a decision from the United States Court of Appeals for the Federal Circuit that invalidated the claim of U.S. Patent 5,800,808 (the “’808 patent”). The 808 patent expires on September 1, 2015 and claims a process for manufacturing  Read More »
March 20, 2014
Teva to Report First Quarter 2014 Financial Results on May 1, 2014
JERUSALEM--(BUSINESS WIRE)--Mar. 20, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its first quarter 2014 financial results on Thursday, May 1, 2014 at 7:00 a.m. ET. Teva will host a conference call and live webcast on the same day, at 8:00 a.m. ET to discuss its first quarter 2014 results and overall business environment. A Question & Answer session will follow this discussion.   Read More »
March 13, 2014
Teva Hosts UK and Israeli Prime Ministers at UK-Israel Innovation Event – Announce Collaboration on New National Clinical Drug Development Initiative and Dementia Research
Teva to collaborate on new UK Government-led clinical drug development initiative The initiative creates a single point of entry into the UK health system reducing complexity and increasing speed, efficiency of running drug development programs Teva plans to invest approximately $20 million in clinical development in the UK and up to an additional $1 million for basic research into dementia – one of th  Read More »
March 10, 2014
Teva Pharmaceuticals and Volunteers in Medicine Partner to Expand Access to Healthcare in the U.S.
NORTH WALES, Pa. & BURLINGTON, Vt.--(BUSINESS WIRE)--Mar. 10, 2014-- Teva Pharmaceuticals USA, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Volunteers in Medicine (VIM), a national nonprofit organization dedicated to helping communities provide free primary healthcare clinics for families and individuals, today announced their 2014 National Partnership to make healthcare services more readily available to the uninsured.   Read More »
March 07, 2014
Teva Announces Launch of Generic Xeloda® Tablets 150 MG and 500 MG in the United States
JERUSALEM--(BUSINESS WIRE)--Mar. 7, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces the launch of the generic equivalent to Xeloda® (Capecitabine) Tablets, 150 MG and 500 MG, in the United States. Xeloda® is marketed by Genentech in the United States. Teva was the first to receive approval on its ANDA from the U.S. Food and Drug Administration on September 16, 2013 and is launching today per a settlement agreement. Xeloda  Read More »
March 04, 2014
Teva Announces Approval of Generic Evista® Tablets 60 mg in the United States
JERUSALEM--(BUSINESS WIRE)--Mar. 4, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announces the approval of the generic equivalent to Evista® (Raloxifene) Tablets, 60 mg, in the United States. Teva was first to file, making the product eligible for 180 days of marketing exclusivity. Teva will begin shipping the product within the next 30 days. Evista® 60 mg Tablets marketed by Eli Lilly and Company, had annual sales of approximate  Read More »
March 03, 2014
Teva Launches ADASUVE® in U.S.
The first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults JERUSALEM--(BUSINESS WIRE)--Mar. 3, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today the commercial launch of ADASUVE® (loxapine) inhalation powder 10 mg, the first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disor  Read More »
February 28, 2014
Teva to Present at the Cowen & Company 34th Annual Healthcare Conference
JERUSALEM--(BUSINESS WIRE)--Feb. 28, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will host a live audio webcast at the Cowen & Company 34th Annual Healthcare Conference in Boston, MA. Eyal Desheh, EVP & CFO will present on Tuesday, March 4, 2014 at 11:20 AM EST What:   Teva Presentation at the Cowen & Company 34th   Read More »
February 24, 2014
Teva Files 2013 Annual Report on Form 20-F
JERUSALEM--(BUSINESS WIRE)--Feb. 24, 2014-- In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (“Teva”) announced today that it has filed its 2013 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The Annual Report can be found on the company’s website at www.tevapharm.com as well as on the SEC website at www.sec.gov. In addition, securi  Read More »
February 24, 2014
Teva to Present at the Citi 2014 Global Healthcare Conference
JERUSALEM--(BUSINESS WIRE)--Feb. 24, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the Citi 2014 Global Healthcare Conference in New York, NY. Dr. Michael Hayden, President of Global R&D & CSO will present on Wednesday, February 26, 2014 at 1:50 PM EST   What:   Read More »
February 21, 2014
Teva Completes Tender Offer for NuPathe Inc. Shares
Merger Expected to Close Today 80% of Shares Tendered JERUSALEM--(BUSINESS WIRE)--Feb. 21, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (“Teva”) today announced the successful completion of the tender offer (the “Offer”) by Train Merger Sub, Inc. (“Merger Sub”), a wholly-owned subsidiary of Teva, for all of the outstanding shares of common stock of NuPathe Inc. (Nasdaq:PATH) (“NuPathe”) at a price of $3.65 per share in cash a  Read More »
February 21, 2014
Teva Receives CHMP Positive Opinion for DuoResp® Spiromax® for the Treatment of Patients Diagnosed with Asthma and COPD in Europe
Innovative new inhaler for asthma and COPD patients JERUSALEM--(BUSINESS WIRE)--Feb. 21, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorization for DuoResp® Spiromax® (budesonide & formoterol fumarate dihydrate) inhalation powder for the treatment of patients with asthma and chronic obstructive pulmonary disease  Read More »
February 13, 2014
Teva Announces Full FDA Approval of SYNRIBO® (Omacetaxine Mepesuccinate) for Injection
24-Month FDA Post Marketing Commitment Completed JERUSALEM--(BUSINESS WIRE)--Feb. 13, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval of SYNRIBO® (omacetaxine mepesuccinate) for injection. This oncology portfolio product received an accelerated approval in October, 2012 with additional clinical trial data required to fulfill post marketing requir  Read More »
February 06, 2014
Teva Reports Fourth Quarter and Full Year 2013 Results
Fourth Quarter 2013 Net Revenues of $5.4 Billion and Full Year Net Revenues of $20.3 Billion Fourth Quarter 2013 Non-GAAP EPS of $1.42, GAAP diluted EPS of $0.45; Full Year Non-GAAP EPS of $5.01, GAAP diluted EPS of $1.49 COPAXONE® Remains the Leading Global MS Therapy with Record Annual Revenues of $4.3 Billion Robust Cash Flow Supports Return to Shareholders, Capital Expenditures, Deb  Read More »
January 28, 2014
Teva Announces U.S. FDA Approval of Three-Times-a-Week COPAXONE® (glatiramer acetate injection) 40mg/mL
New Formulation of COPAXONE® Offers Patients and Their Physicians Ability to Dose Less Frequently JERUSALEM--(BUSINESS WIRE)--Jan. 28, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved the Company’s supplemental new drug application (sNDA) for three-times-a-week COPAXONE® 40mg/mL, a new dose of COPAXONE®. This new formulation will allow for a less frequent dosi  Read More »
January 24, 2014
Teva and Active Biotech Remain Committed to the Development of NERVENTRA® (laquinimod) for Multiple Sclerosis Following the Negative Opinion from the EMA’s CHMP
JERUSALEM & LUND, Sweden--(BUSINESS WIRE)--Jan. 24, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that both companies remain committed to the NERVENTRA® (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for H  Read More »
January 21, 2014
Teva Expands CNS Specialty Business with Acquisition of NuPathe
JERUSALEM--(BUSINESS WIRE)--Jan. 21, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that it has entered into a definitive agreement under which Teva will acquire NuPathe Inc. (Nasdaq:PATH) for $3.65 per share in cash, or approximately $144 million. In addition to the upfront cash payment, NuPathe shareholders will receive rights to receive additional cash payments of up to $3.15 per share if specified net sales of NuPathe’s migrai  Read More »
January 13, 2014
Data Demonstrates Key Genes Respond Differently to COPAXONE® (glatiramer acetate injection) Versus a Purported Generic Glatiramer Acetate
Multiple genes associated with potential therapeutic effects expressed differently: Gene expression analysis provides insight into variability JERUSALEM--(BUSINESS WIRE)--Jan. 13, 2014-- Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA) today announced the publication of data that demonstrates significant differences in biological and immunological effects between COPAXONE® (glatiramer acetate, GA) and a purported generic glatiramer acetate   Read More »
January 09, 2014
Teva to Present at the 32nd Annual J.P. Morgan Healthcare Conference
JERUSALEM--(BUSINESS WIRE)--Jan. 9, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will host a live audio webcast at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Eyal Desheh, Acting President & CEO will present on Tuesday, January 14, 2014 at 10:30 AM PT.   What:     Read More »
January 09, 2014
Teva Names Erez Vigodman as President and CEO
Brings global leadership and business transformation experience Provides strong strategic expertise across multiple industries and deep insight into global market dynamics JERUSALEM--(BUSINESS WIRE)--Jan. 9, 2014-- Teva Pharmaceutical Industries Ltd (NYSE:TEVA) today announced that Erez Vigodman, 54, has been appointed President and Chief Executive Officer, effective February 11, 2014. Mr. Vigodman will succeed acting Pres  Read More »
January 03, 2014
Teva Announces Launch of Authorized Generic of Detrol®
JERUSALEM--(BUSINESS WIRE)--Jan. 3, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the launch of the Authorized Generic of Detrol®* LA (tolterodine tartrate extended-release capsules) 2 mg and 4 mg in the U.S. market. Detrol® LA had annual sales of approximately $571.5 million in the U.S., according to IMS data as of September 30, 2013. *Detrol® is a registered trademark of Pfizer Enterprises Sarl. About Te  Read More »
 Previous | Next